Brooklyn ImmunoTherapeutics Total Revenue

As of the most recent data (September 2024), BTX shows a total revenue of $600K. That compares with $51K in the prior-year period — up 1072.5% year over year. That is below the Telecommunications sector average of $1.7T. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BTX's total revenue is now $600K (was $51K) — a 1072.5% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Brooklyn ImmunoTherapeutics is outperforming or lagging.

The Telecommunications sector average total revenue is about $1.7T. Brooklyn ImmunoTherapeutics is at $600K, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how BTX stacks up against individual peers as well.

Tracking BTX's total revenue over time shows whether Brooklyn ImmunoTherapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $600K That compares with $51K in the prior-year period — up 1072.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total revenue page, Stockcircle has Brooklyn ImmunoTherapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total revenue (currently $600K) with ownership activity and broader fundamentals.